The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Practice · Dosing & titration

Titrating on tolerability rather than on the calendar — the long version

MD
m.dumitruTL2 Moderator13 Oct 2024#1

Titrating on tolerability rather than on the calendar — the long version Writing it up because I had to work it out twice and would rather nobody else did.

Reporting something rather than asking about it, in case the pattern is useful to anyone else.

Over 23 weeks I logged this consistently: date, dose, time of day, and a simple severity score from 0 to 4 for each symptom. That is 157 data points, all self-reported, all unblinded, and collected by someone who knew what he expected to find. Treat it accordingly.

The reason I am posting is that my experience does not match the shape people usually describe here, and I would like to know whether that is unusual or whether the usual description is just the loudest version.

10 likes 21mo
OA
o.abrahamsenTL3Regular6 Jan 2025#2

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

0 likes 19mo
RM
r.molnarTL2 Moderator7 Mar 2025#3
o.abrahamsen, post #2: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

29 likes in reply to #2 17mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Escalating every six weeks instead of four: what I observed over eight months
Escalating every six weeks instead of four: what I observed over eight months Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
RMKCCLHETP+27 31 432 18mo
Holding a dose indefinitely: is there a documented downside?
Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I have…
HFOBRSPPBD+28 32 57k 12mo
Revisiting: The arithmetic of an intermediate dose between two label steps
Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
CSRHGBWTMR+41 45 808 2mo
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than asking about it, in case the…
LWPADMHKM+31 35 2k 1d
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
EFCCBKEM+98 102 26k 3mo

Related topics — sharing the tags worked example, missed dose, titration

TopicParticipantsRepliesViewsActivity
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
RIPREAGTMM+2 6 5.5k 7h
Escalating every six weeks instead of four: what I observed over eight months
Escalating every six weeks instead of four: what I observed over eight months Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
RMKCCLHETP+27 31 432 18mo
Leak-back after withdrawal and whether you lost a meaningful dose
Posting this under the heading it deserves: Leak-back after withdrawal and whether you lost a meaningful dose Everything below is what sits behind that. Reporting something rather than asking about it, in…
SDJPB 2 3k 3h
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
BRIJVPYR+7 11 31k 17mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…
TTARHMKRMC+7 11 281 6mo